321 related articles for article (PubMed ID: 32496443)
1. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.
Breese EH; Krupski C; Nelson AS; Perentesis JP; Phillips CL
J Pediatr Hematol Oncol; 2021 May; 43(4):152-154. PubMed ID: 32496443
[TBL] [Abstract][Full Text] [Related]
2. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.
Moskop A; Pommert L; Thakrar P; Talano J; Phelan R
Pediatr Blood Cancer; 2021 Jan; 68(1):e28739. PubMed ID: 33009894
[TBL] [Abstract][Full Text] [Related]
6. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
7. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
10. Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.
Liao W; Kohler ME; Fry T; Ernst P
Exp Hematol; 2021 Aug; 100():1-11. PubMed ID: 34298117
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in
Fournier E; Inchiappa L; Delattre C; Pignon JM; Danicourt F; Bemba M; Roche-Lestienne C; Daudignon A; Decool G; Roumier C; Dumezy F; Fournier L; Grardel N; Preudhomme C; Duployez N
Leuk Lymphoma; 2019 Jul; 60(7):1827-1830. PubMed ID: 30616415
[No Abstract] [Full Text] [Related]
13. Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.
Sarkar S; Rav E; Stitzlein L; Gibson A; McCall D; Nunez C; Roth M; Ragoonanan D; Connors J; Herzog CE; Cuglievan B; Garcia MB
Pediatr Blood Cancer; 2024 Jun; 71(6):e30964. PubMed ID: 38514796
[No Abstract] [Full Text] [Related]
14. CAR T-cells in acute lymphoblastic leukemia: Current results.
Dourthe ME; Baruchel A
Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
17. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
[TBL] [Abstract][Full Text] [Related]
18. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
